More info
Active ingredients
Bacteria Lysates [Hemophilus influenzae + Streptococcus pneumoniae + Streptococcus viridans + Streptococcus pyogenes + Klebsiella pneumoniae + Klebsie
Release form
Capsules
Composition
The following items are provided in the first section of the voucher; - 3.03 mg, mannitol - to obtain 40 mg, starch pregelatinized - 110 mg, magnesium stearate - 3 mg, mannitol - to obtain 200 mg.
Pharmacological effect
Immunostimulating drug of bacterial origin. Causes the immune response of the mucous membrane of the digestive tract. Especially the effect is manifested in Peyer's patches of small intestine. Antigen presenting cells (APC) in PB are activated by the drug and subsequently stimulate the cells responsible for specific immunity. An increase in the number of circulating B lymphocytes is observed with the use of the drug. After stimulation of B-lymphocytes, an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the mucous membrane of the respiratory tract and saliva is observed. These antibodies are the first line of defense against a number of infectious agents (viruses and bacteria). The drug has a powerful stimulating effect on most types of white blood cells, as evidenced by the increase in the number of myeloid and lymphoid cells, as well as a selective increase in the expression of receptors on their surface. In aggregate These data confirm that the drug triggers biological reactions that increase the body’s immune defenses against infection. Clinically Broncho-Vaks; an adult reduces the frequency of acute respiratory tract infections, shortens the duration of their course, reduces the likelihood of exacerbation of chronic bronchitis, and also increases the body's resistance to infections of the respiratory system. This reduces the need for the use of other drugs, especially antibiotics.
Indications
Adults and children aged 12 years and older: - prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis; - treatment of acute respiratory tract infections (as part of complex therapy).
Contraindications
Pregnancy; lactation period; hypersensitivity to the drug.
Use during pregnancy and lactation
Experimental studies on animals have not revealed any negative effects on the course of pregnancy, but due to the fact that there are no data on the use of the drug in pregnant and lactating women, its use during pregnancy and during breastfeeding is contraindicated.
Dosage and administration
Broncho-Vaks; an adult is prescribed to adults and children aged 12 years and older. With the aim of treating acute and exacerbating chronic infections of the respiratory tract: 1 capsule of the drug Broncho-Vax; adult daily in the morning on an empty stomach until the symptoms disappear, but not less than 10 days. If necessary, antibiotic therapy Broncho-Vaks; An adult should be taken in combination with an antibiotic from the start of treatment. The doctor should determine the duration of treatment based on the patient's health. To prevent exacerbations and maintenance therapy: 1 capsule of Broncho-Vax; adult daily in the morning on an empty stomach. The course includes 3 cycles, each of which consists of taking 1 capsule daily for 10 days, the interval between cycles is 20 days. In case the capsule is difficult to swallow, open it and mix the contents with drink (water, fruit juice, milk).
Side effects
Broncho-Vaks; an adult is usually well tolerated. Most of the adverse reactions are classified as general or moderate to moderate. The most frequent manifestations of side effects of the drug are skin reactions, disorders of the digestive tract and respiratory organs. In each particular category, side effects are grouped by systemic organ class and presented in decreasing order of frequency: very often (≥1 / 10); often (from 1/100 to 1/10); infrequently (from 1/1000 to 1/100); rarely (from 1/10 000 to 1/1000); very rarely (<1/10 000); unknown (based on available data, evaluation is not possible). From the digestive system: often - diarrhea, abdominal pain; unknown - vomiting, nausea. From the nervous system: unknown - headache. From the respiratory system: often - cough. Dermatological reactions: often - rash. Allergic reactions: infrequent - hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema of the eyelids , swelling of the face, peripheral edema, swelling of the face, itching, generalized itching, shortness of breath); unknown - urticaria, angioedema. Others: unknown - fever, fatigue.
Overdose
Information about cases of overdose are absent.The nature of the drug Broncho-Vaks; an adult and results of a study of its toxicity indicate that overdose is unlikely.
Interaction with other drugs
Broncho-Vaks; an adult can be used simultaneously with other drugs for the treatment of acute and chronic respiratory diseases. The drug interaction Broncho-Vaks; an adult with other medications has not yet been established.
special instructions
The components of the drug can cause hypersensitivity reactions. In the case of persistent gastrointestinal disorders, skin reaction, respiratory disorders or other symptoms of intolerance to the drug, treatment should be stopped, because These symptoms are a manifestation of an allergic reaction. Effects on the ability to drive vehicles and control mechanisms: Broncho-Vaks; an adult does not affect the ability to drive vehicles and work with mechanisms.